NCT07444619 2026-03-03
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
Clinical Trials
8 trialsNCT07401875 2026-02-27
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07430202 2026-02-24
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Not yet recruiting
NCT07403877 2026-02-11
TORCH-OPTIMA
Fudan University
Phase 2 Not yet recruiting
NCT07355205 2026-01-21
FLINN
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT07338981 2026-01-14
The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.
British Columbia Cancer Agency
Phase 3 Not yet recruiting
NCT07233668 2025-12-03
IVE in mRCC
Seoul National University Hospital
Phase NA Not yet recruiting
NCT07075120 2025-10-28
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Not yet recruiting